Author

Antonella Folgori

ORCID 0000-0003-2344-2816Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Immunology· 2 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1

Frequent Co-Authors

Stefania CaponeiD· 3 shared Stefano Colloca· 3 shared Angelo RaggioliiD· 2 shared Michela Gentile· 2 shared Tariro MakadzangeiD· 2 shared Adriano Leuzzi· 1 shared Adrianus C. M. BooniD· 1 shared Alan DodsoniD· 1 shared

Activity by Year

2023-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Stefania CaponeORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologybioRxivPreprintMay 26, 2026

Low seroprevalence of neutralizing antibodies to gorilla adenovirus 32 (GRAd32) in southern African populations supports evaluation of this vector platform for HIV vaccine development

Nonhlanhla N. Mkhize, Anna patjane, Nomcebo Shusha…·Penny L. Moore

This study finds low neutralizing antibody prevalence to GRAd32 in southern African populations, suggesting its potential as an HIV vaccine vector despite prior Ad26 vaccination.

DOI 10.64898/2026.05.23.726423

humanproteomics

𝕏 PostBluesky

Pharmacology & ToxicologyVaccinesPeer-reviewedFeb 6, 2026

Non-clinical safety of GRAd vector-based COVID-19 and HIV vaccines supports a platform regulatory approach

Reji Paalangara, Stéphanie Gohin, Alexis Menard…·Stefania Capone

This study evaluates the non-clinical safety of two GRAd vector-based vaccines for COVID-19 and HIV, showing consistent safety profiles and supporting a regulatory platform approach.

2 citationstop 4%

rathuman

𝕏 PostBluesky

ImmunologybioRxivPreprintNov 22, 2023

Durable immunity to SARS-CoV-2 in both lower and upper airways achieved with a gorilla adenovirus (GRAd) S-2P vaccine in non-human primates

Juan I. Moliva, Shayne F. Andrew, Barbara J. Flynn…·Nancy J. Sullivan

This study shows a gorilla adenovirus-based vaccine provides durable immunity against SARS-CoV-2 in both airways of non-human primates, with enhanced protection from aerosol delivery and prime-boost regimens.

5 citations

non-human primateproteomics

𝕏 PostBluesky